VVOS logo

VVOS
Vivos Therapeutics Inc

5,503
Mkt Cap
$12.67M
Volume
157,022.00
52W High
$7.95
52W Low
$1.09
PE Ratio
-0.61
VVOS Fundamentals
Price
$1.21
Prev Close
$1.16
Open
$1.18
50D MA
$1.39
Beta
0.82
Avg. Volume
117,383.75
P/B
3.95
Loading...
Loading...
News
all
press releases
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.read more...
Benzinga·6d ago
News Placeholder
More News
News Placeholder
Insider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Buys 1,353,625 Shares of Stock
Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) major shareholder Michael Skaff purchased 1,353,625 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was...
MarketBeat·9d ago
News Placeholder
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.9% stake through a $2.39 million private placement.read more...
Benzinga·9d ago
News Placeholder
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of -14.26% and +1.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.69% and +107.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest VVOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.